CJC-1295 (no DAC)
Mod GRF 1-29 / Modified GRF
CJC-1295 (without DAC) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) consisting of amino acids 1-29 of GHRH with amino acid substitutions to increase stability and receptor binding affinity. Also known as Modified GRF(1-29) or Mod GRF, it produces pulsatile growth hormone release that more closely mimics natural physiology compared to the DAC variant. It is most commonly combined with a GHRP such as Ipamorelin to amplify GH output through dual-pathway stimulation.
작용 메커니즘
Modified growth hormone releasing hormone (GHRH) analog with amino acid substitutions at positions 2, 8, 15, and 27 to prevent enzymatic degradation. Stimulates pituitary GHRH receptors to amplify natural GH pulses without extending the pulse duration.
연구 프로토콜
연구 용도만 사용 가능. 의학적 조언은 아닙니다.
Research protocols use 100-200mcg 2-3 times daily via subcutaneous injection, typically combined with a GHRP (ipamorelin, GHRP-2, or GHRP-6). Administer on empty stomach 30 min before or 2 hours after meals.
연구 노트
Clinical Research Status
CJC-1295 without DAC has been studied in clinical trials demonstrating dose-dependent increases in GH and IGF-1 levels. The no-DAC version has a short half-life of approximately 30 minutes, requiring more frequent dosing but producing GH pulses rather than sustained elevation. No FDA approval exists for any indication; it remains an investigational compound available through research suppliers.
Key Published Findings
Clinical studies show that Modified GRF(1-29) increases GH secretion 2-10 fold when administered subcutaneously. Combination with GHRPs produces synergistic effects, with GH output greater than either compound alone. Research demonstrates improvements in body composition, sleep quality, and recovery markers in study participants over 4-12 week protocols.
Safety Profile
Side effects are generally mild and include transient flushing, headache, dizziness, and injection site reactions. Unlike exogenous GH, it preserves the hypothalamic-pituitary feedback loop, reducing risk of GH excess. Water retention and joint stiffness may occur at higher doses, consistent with elevated IGF-1 levels.
Drug Interactions & Contraindications
Should not be combined with somatostatin analogs (e.g., octreotide) which directly oppose its mechanism. Caution advised with glucocorticoids which suppress the GH axis. Contraindicated in individuals with active malignancy due to IGF-1's proliferative effects on certain cancer types.
Comparison to Related Compounds
The no-DAC version produces a short GH pulse (~30 min half-life) versus CJC-1295 with DAC which elevates GH for 6-8 days due to albumin binding. Most practitioners prefer no-DAC for its more physiological pulsatile pattern and lower risk of prolonged IGF-1 elevation. Sermorelin is an older, less potent GHRH analog that CJC-1295 has largely replaced in research settings.
Community Observations
Typically dosed at 100-300mcg subcutaneously 1-3 times daily, most commonly before bed and upon waking. The combination of Mod GRF + Ipamorelin at 100mcg each is considered the standard research protocol for GH optimization. Users report improved sleep quality, faster recovery, and gradual improvements in body composition over 3-6 month protocols.
반감기
~30 minutes
재조성
Bacteriostatic water (BAC)
보관
건조한 상태
Refrigerate 2-8C up to 18 months.
재조성된 상태
Refrigerate 2-8C. Use within 14 days.
미국 법적 상태
또는 알려진 이름으로
자주 묻는 질문
CJC-1295 (no DAC)란 무엇인가요?
CJC-1295 (without DAC) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) consisting of amino acids 1-29 of GHRH with amino acid substitutions to increase stability and receptor binding affinity. Also known as Modified GRF(1-29) or Mod GRF, it produces pulsatile growth hormone release that more closely mimics natural physiology compared to the DAC variant. It is most commonly combined with a GHRP such as Ipamorelin to amplify GH output through dual-pathway stimulation.
CJC-1295 (no DAC)는 어떻게 작용하나요?
Modified growth hormone releasing hormone (GHRH) analog with amino acid substitutions at positions 2, 8, 15, and 27 to prevent enzymatic degradation. Stimulates pituitary GHRH receptors to amplify natural GH pulses without extending the pulse duration.
CJC-1295 (no DAC)의 미국 규제 현황은 어떤가요?
Research chemical (not FDA-approved)
CJC-1295 (no DAC)의 반감기는 얼마인가요?
~30 minutes
CJC-1295 (no DAC)의 다른 이름은 무엇인가요?
Mod GRF 1-29, Modified GRF
Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.
전체 공지사항 읽기